Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Pricing Experiment Won't Extend To Part D, Senate Panel Told

This article was originally published in The Pink Sheet Daily

Executive Summary

CMS Deputy Administrator Conway's appearance at the Finance Committee prompted questions about a theoretical next demonstration project while members challenged the project currently on the table; Conway suggested some ‘adjustments’ are coming to the proposed Part B demo.

You may also be interested in...

Trump, Congress And The Search For Common Ground On Drug Pricing

Trump’s ideas for curbing drug pricing have support in Congress but not among those in power; Republican leaders, including the president-elect’s choice for HHS secretary, Tom Price, have long opposed government negotiation in Medicare.

Part B Reference Pricing Faces 'Clinical' As Well As 'Political' Obstacles

Medicare pilot program on value-based purchasing could be challenged by a lack of therapeutic consensus as much as by opposition towards reduced reimbursement.

Have You Heard The Latest Rumor On Drug Pricing? Orrin Hatch Has

An exchange during HHS Secretary Burwell’s testimony to the Finance Committee on the fiscal 2017 budget speaks volumes about what is – and is not – on the table for the last year of the Obama Administration.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts